- Home
- DPC vs ORKA Comparison
DPC vs ORKA Comparison
Compare DPC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPC | ORKA |
|---|---|---|
| Founded | N/A | 2004 |
| Country | | United States |
| Employees | N/A | 68 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | DPC | ORKA |
|---|---|---|
| Price | $45.84 | $93.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $92.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.50 | $12.84 |
| 52 Week High | $53.50 | $97.78 |
Technical Indicators
Market Signals| Indicator | DPC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 64.62 |
| Support Level | $44.41 | $27.81 |
| Resistance Level | $50.79 | $97.78 |
| Average True Range (ATR) | 3.73 | 5.43 |
| MACD | -0.25 | -0.34 |
| Stochastic Oscillator | 22.80 | 77.49 |
Price Performance
Historical ComparisonAbout DPC DPC Holdings PLC Ordinary Shares
DPC Holdings PLC is a manufacturer of complex precision cast components for aerospace engines and industrial gas turbines. It produces metal components and specialized products for aerospace and industrial applications and operates manufacturing facilities across multiple locations globally.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.